The Science and Policy Advisory Council provides a disruptive force in our dynamic healthcare forum through expert observations and recommendations on DIA's content strategies, essential research questions, key opinion leaders, collaboration partners, and trends affecting the future life sciences landscape.
Fellow of DIA
Nancy Dreyer, MPH, PhD, is Chief Scientific Officer and Senior Vice President at IQVIA, focusing on generating real world evidence for regulators, clinicians, patients and payers through pragmatic trials and non-interventional approaches. She is a Fellow of DIA and the International Society of Pharmacoepidemiology, a member of the PCORI Clinical Trials Methods Advisory Panel, and a Standing Consultant to the National Football League Health & Safety Executive Committee. She holds an appointment as Adjunct Professor of Epidemiology at the Gillings School of Global Public Health at the University of North Carolina and has twice been named to PharmaVOICE magazine's annual list of 100 most influential and inspiring individuals in life sciences.
Yeul Hong Kim
Yeul Hong Kim, MD, PhD, is a Professor in the Department of Internal Medicine at the Korea University College of Medicine in Seoul. He is actively involved in cancer genomic research, using circulating tumor DNA, for lung and gastrointestinal cancers. His primary area of interest is in the development of new therapies in gastric cancer, colon cancer, and other gastrointestinal cancers including pancreatic cancer and biliary cancer. Dr. Kim has also served as President of the Asian Clinical Oncology Society since 2016. He is also Director of the K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, a cancer precision medicine project funded by the Korea Ministry of Health and Welfare.
Sandra A. Milligan
Fellow of DIA
Merck Research Laboratories
Sandra Milligan is head of Global Regulatory Affairs and Clinical Safety (GRACS) at Merck. GRACS optimizes regulatory plans to facilitate innovative product development, regulatory approval and commercialization around the world, assures the safe use of products worldwide, and maintains registrations for over 200 products across 183 international markets. She served as program chair on DIA’s Board of Directors from 2011 to 2017, and as President of DIA from 2015 to 2016. In 2017, Sandra was recognized as a DIA Fellow for her engagement and contributions to the mission of DIA and was appointed to DIA’s Science Advisory Council in 2018. She is a graduate of George Washington University School of Medicine and Georgetown University Law Center.
Samuel R. Nussbaum
EBG Advisors, Inc.
Samuel R. Nussbaum, MD, serves as an advisor to healthcare companies, healthcare systems, and healthcare provider organizations, as a Strategic Consultant with EBG Advisors, Inc. He is a Senior Fellow at the Schaeffer Center for Health Policy and Economics at the University of Southern California, and previously served as Executive Vice President, Clinical Health Policy, and Chief Medical Officer, for Anthem, and as Executive Vice President for BJC HealthCare. Dr. Nussbaum earned his Medical Degree from the Icahn School of Medicine at Mount Sinai.
Michael Rosenblatt, MD, Chief Medical Officer of Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several biotech companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Children’s Hospitals. He earned his MD from Harvard Medical School.
Joe V. Selby
Patient-Centered Outcomes Research Institute
Joe Selby, MD, is the first Executive Director of the Patient-Centered Outcome Research Institute (PCORI). He previously served for nearly three decades, including 13 years as Director of Research, at Kaiser Permanente. Dr. Selby has received academic appointments at UC Berkeley, UCSF and Stanford University, and has received honors from Kaiser Permanente, the US Public Health Service, and the American Epidemiological Society. Dr. Selby served as a member of the Agency for Healthcare Research and Quality study section for Health Care Quality and Effectiveness (1999 – 2003) and was elected to membership in the US Institute of Medicine in 2009. Dr. Selby earned his MD from Northwestern University and MPH from UC Berkeley.
Jonathan Gary Sheldon
Jonathan Sheldon, PhD, is Senior Vice President and member of the Executive Committee at QIAGEN, leading the Bioinformatics Business Unit and contributing to the QIAGEN governing body responsible for defining corporate strategy. Dr. Sheldon previously served as Global Vice President Healthcare at Oracle, and has held various CXO positions in software companies serving both the life science and healthcare sectors. Prior to the software industry, Dr. Sheldon was Head of Bioinformatics for five years at Roche (UK) Pharmaceuticals. Dr. Sheldon has been served on various advisory groups and boards including as a Director of the tranSMART Foundation, and earned his PhD in Molecular Cell Biology from the University of Cambridge.
Fellow of DIA
Shenyang Pharmaceutical University
Ling Su, PhD, is Professor and Director, Institute of Drug Regulatory Science in Shenyang Pharmaceutical University, and a Venture Partner with Lilly Asia Ventures. Dr. Su has over 25 years of experience in drug regulatory and development. He had worked in the Chinese regulatory agency and US FDA, as well as in various R&D management positions in the pharma industry, including VP for Clinical Research Asia Pacific at Wyeth, and SVP and Head of Pharma Development China at Novartis. In addition, he is a Research Fellow at the Research Center of National Drug Policy & Ecosystem, China Pharmaceutical University and an inaugural member of the Biotech Expert Advisory Panel of Hong Kong Stock Exchange. He is the past president and a Fellow of DIA.
Editas Medicine Inc.
Ms. Katrine S. Bosley has been the Chief Executive Officer and President of Editas Medicine Inc. since June 24, 2014. Ms. Bosley served as the Chief Executive Officer at Celgene Avilomics Research, Inc. She served as Vice President of Business Development at Adnexus Therapeutics Inc. She served as Vice President of Strategic Operations at Adnexus Therapeutics Inc. since August 2004. She has been a leader in emerging companies with broad platforms for innovative medicines. She has over 20 years experience in the biotechnology industry in the U.S. and in Europe.
Margaret A. Hamburg
The National Academies of Science, Engineering and Medicine
Dr. Hamburg is an internationally recognized leader in public health and medicine. She is the former Commissioner of the U.S. Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service. As FDA Commissioner she was known for advancing regulatory science, streamlining and modernizing FDA’s regulatory pathways, and globalization of the agency. Before joining FDA, Dr. Hamburg was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical and biological threats. Dr. Hamburg earned her B.A. from Harvard College, her M.D. from Harvard Medical School and completed her medical residency at Weill Cornell Medical Center.